Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.

Publikation

Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.

Wissenschaftlicher Artikel/Review - 10.10.2023

Begré Lorin, Boyd Anders, Salazar-Vizcaya Luisa, Suter-Riniker Franziska, Béguelin Charles, Rockstroh J K, Günthard Huldyrich F, Calmy Alexandra, Cavassini Matthias, Stoeckle Marcel, Schmid Patrick, Bernasconi Enos, Levrero Massimo, Zoulim Fabien, Wandeler Gilles, Rauch Andri, Swiss HIV Cohort Study (SHCS)

Zitation

Begré L, Boyd A, Salazar-Vizcaya L, Suter-Riniker F, Béguelin C, Rockstroh J, Günthard H, Calmy A, Cavassini M, Stoeckle M, Schmid P, Bernasconi E, Levrero M, Zoulim F, Wandeler G, Rauch A, Swiss HIV Cohort Study (SHCS). Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy. HIV Med 2023; 25:291-298.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

HIV Med 2023; 25

Veröffentlichungsdatum

10.10.2023

eISSN (Online)

1468-1293

Seiten

291-298

Kurzbeschreibung/Zielsetzung

Improving the understanding of the patterns of quantitative hepatitis B surface antigen (qHBsAg) trajectories associated with HBsAg loss is important in light of novel anti-hepatitis B virus agents being developed. We evaluated long-term qHBsAg trajectories in persons with HIV and HBV during tenofovir-containing antiretroviral therapy in the Swiss HIV Cohort Study.